YAP1 and cancer: However, it is still possible that other molecular events may control YAP activation in >65% of HNSCC cases that do not exhibit YAP1 or FAT1 genomic alterations, whose elucidation may help reveal new molecular mechanisms controlling the Hippo pathway in cancer.